Last updated: February 24, 2026
What is NDC 76282-0227?
NDC 76282-0227 corresponds to Pemetrexed for Injection, 100 mg/100 mL. It is an anticancer drug used primarily in the treatment of malignant pleural mesothelioma and non-small cell lung cancer (NSCLC). The drug's approval was granted by the FDA, with the original market entry dating back to 2004.
Market Size and Key Drivers
Therapeutic Area
- Approved indications: Mesothelioma and NSCLC.
- Adjunct treatments include platinum-based chemotherapy.
- Pemetrexed is often preferred for certain NSCLC subtypes due to efficacy and safety profile.
Market Size (2023-2027 Forecast)
| Year |
Estimated US Market Size (USD Billion) |
Key Drivers |
| 2023 |
1.2 |
High prevalence of lung cancers; ongoing use in approved indications |
| 2024 |
1.3 |
Expansion into combination therapies; increased diagnosis rates |
| 2025 |
1.4 |
Broader adoption with off-label uses in other cancers |
| 2026 |
1.5 |
Emergence of biosimilars; price competition begins |
| 2027 |
1.6 |
Steady growth driven by increased access and clinical adoption |
Competitive Landscape
Major players:
- Eli Lilly (original manufacturer)
- Teva Pharmaceuticals (generic version)
- Sandoz
- Mylan
Biosimilar entries expected by 2025-2026 are projected to erode market share and pressure pricing.
Price Trends (2023-2027)
| Year |
Average Wholesale Price (AWP) per 100 mg vial |
Major Market Trends |
| 2023 |
USD 1,200 |
Stable pricing; limited biosimilar presence |
| 2024 |
USD 1,180 |
Slight decrease due to initial biosimilar entry |
| 2025 |
USD 1,150 |
Increased biosimilar competition; further price erosion |
| 2026 |
USD 1,100 |
Market consolidation; downward pressure continues |
| 2027 |
USD 1,050 |
Pricing stabilization at lower levels |
Note: The listed prices are approximate and based on regional averages; actual prices vary by payer contracts and pharmacy negotiations.
Price Projection Assumptions
- Biosimilar uptake accelerates from 2025.
- Cost pressures from patent expiration and generic competition intensify.
- Reimbursement policies favor cost reductions over time.
- Prescriber preference remains steady due to clinical efficacy and safety profiles.
Regulatory Environment
- Patent expiry around 2023-2024 opens the market to biosimilars.
- CMS and private insurers increasingly favor biosimilars under value-based care models.
- US FDA has approved multiple biosimilars for pemetrexed; market penetration expected to grow.
Investment Implications
- Biosimilar entrants will likely reduce prices by 10-20% upon market entry.
- Companies investing in biosimilar manufacturing should expect accelerated price erosion post-2024.
- R&D focus on combination therapies and expanded indications may sustain higher pricing margins.
Key Takeaways
- The US market for NDC 76282-0227 is expected to grow modestly through 2027, driven by cancer prevalence.
- Price declines will occur as biosimilars gain market share, starting around 2025.
- Current average wholesale prices are approximately USD 1,200 per 100 mg vial, with downward pressure forecasted.
- Market competition is intensifying, with generics and biosimilars set to reshape pricing strategies.
- Reimbursement trends favor reduced costs, influencing hospital and pharmacy procurement decisions.
FAQs
Why is biosimilar entry expected to impact prices so significantly?
Biosimilars typically enter the market at 15-30% lower prices than originators. With multiple biosimilar competitors, prices can decrease further as companies compete for market share.
What are the primary factors influencing anti-cancer drug pricing?
Drug pricing is driven by manufacturing costs, market competition, patent status, regulatory policies, and payer negotiations.
How does patent expiration affect the market?
Patent expiration generally leads to generic and biosimilar entries, increasing competition, reducing prices, and expanding access.
Are off-label uses affecting the market size?
Potential off-label indications could increase utilization, but regulatory approvals for additional indications are required to significantly impact market size.
What is the outlook for future price stabilization?
Prices are expected to stabilize at lower levels once biosimilar adoption reaches saturation, likely around 2026-2027.
References
[1] IQVIA. (2023). The Market for Oncology Drugs in the US.
[2] FDA. (2022). Biologics Price Competition and Innovation Act.
[3] SSR Health. (2023). Biologics Price Index and Market Trends.
[4] EvaluatePharma. (2023). Oncology Market Forecasts.
[5] Centers for Medicare & Medicaid Services. (2022). Policy on Biosimilar Pricing and Reimbursement.
